Insulet, a medical device company, has reported positive results from the first feasibility study of its Omnipod Horizon hybrid closed-loop system for the treatment of patients with type 1 diabetes.
The Omnipod Insulin Management System is a continuous insulin delivery system designed to provide continuous subcutaneous insulin infusion (CSII) therapy.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It consists of a pod that stores and delivers insulin, in addition to a personal diabetes manager (PDM) that wirelessly programmes the user's personalised insulin delivery, calculates suggested doses and insulin and has a built-in blood glucose meter.
The 36-hour study was conducted in 24 adult patients and involved the use of a modified version of the Omnipod, a Dexcom continuous glucose sensor, and Insulet’s personalised model predictive control algorithm.
The results from the study showed that the Omnipod automated glucose control algorithm performed well, was safe during both day and night and was effective at night with improved fasting glucose and minimal hypoglycemia.
The Omnipod hybrid closed-loop system allowed patients to spend comparitively less time in hypoglycemic blood glucose range.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIt was also found that patients achieved the target blood glucose control range 69% of the time and maintained the target blood glucose control 90% of the time during the overnight period.
The small, light-weight pod of the Omnipod system is claimed to enable the user to wear it in various locations such as the abdomen, hip, back of upper arm, upper thigh or lower back. It is also said to provide up to three days of non-stop insulin delivery.
